How to Get Testosterone Cypionate in California

California Law Permits Telehealth Testosterone Prescriptions

Testosterone cypionate is a Schedule III controlled substance under both federal and California law, but California explicitly permits its prescription via telehealth. Under California Business and Professions Code §2290.5, a provider licensed in the state may prescribe controlled substances after establishing a provider-patient relationship through a real-time audio-video visit. That means you do not need to drive to a brick-and-mortar clinic to start testosterone replacement therapy (TRT).

Several nationwide telehealth platforms now serve California patients specifically because the state's regulatory framework is among the most permissive for remote prescribing. The California Medical Board and Board of Registered Nursing both recognize synchronous telehealth encounters as a valid basis for initiating controlled substance prescriptions, provided the prescriber documents a clinical evaluation and appropriate labs. An in-person physical exam is not required if audio-video assessment is performed.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy only in men with symptomatic androgen deficiency confirmed by at least two morning serum testosterone measurements below 300 ng/dL (Bhasin et al., J Clin Endocrinol Metab, 2018). California prescribers follow this same diagnostic threshold.

What Labs You Need Before Starting

Two fasting, morning blood draws showing total testosterone below 300 ng/dL are the minimum diagnostic requirement. Your provider will also order several other panels to rule out contraindications and establish a safety baseline.

The standard pre-TRT lab panel includes total testosterone, free testosterone (calculated or measured by equilibrium dialysis), luteinizing hormone (LH), follicle-stimulating hormone (FSH), complete blood count (CBC) with hematocrit, comprehensive metabolic panel (CMP), lipid panel, prostate-specific antigen (PSA) for men over 40, and estradiol. LH and FSH help distinguish primary hypogonadism (testicular failure) from secondary hypogonadism (pituitary or hypothalamic dysfunction), which affects treatment decisions.

Hematocrit deserves special attention. The FDA's testosterone product labeling carries a warning about polycythemia, defined as hematocrit exceeding 54%. A baseline hematocrit above 50% may prompt your provider to start at a lower dose or monitor more frequently. The T-Trials, a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older, found that testosterone gel significantly increased hematocrit compared with placebo (Snyder et al., NEJM, 2016). Injectable cypionate tends to produce higher peak levels than gels, making hematocrit monitoring even more relevant.

Most telehealth TRT platforms partner with Quest Diagnostics or Labcorp, both of which operate dozens of draw sites across California. You can typically complete your blood work within 48 hours of ordering, and results return in 2 to 5 business days.

Who Can Prescribe: MD, DO, NP, and PA Scope in California

California grants prescriptive authority for Schedule III controlled substances to physicians (MD/DO), nurse practitioners (NP), and physician assistants (PA). The practical differences matter if you are choosing a provider.

MDs and DOs have independent prescriptive authority with no collaborative agreement required. California Assembly Bill 890, effective January 1, 2023, granted NPs independent practice authority after completing a 4,600-hour transition-to-practice period. NPs who have completed this requirement can prescribe testosterone cypionate without physician supervision. PAs prescribe under a collaborative agreement with a supervising physician, though the physician does not need to co-sign every prescription.

Endocrinologists and urologists typically have the deepest expertise in male hypogonadism, but the American Urological Association notes that primary care providers manage the majority of TRT prescriptions nationally (Mulhall et al., J Urol, 2018). If your symptoms are straightforward, a primary care provider or telehealth clinician with TRT experience is a reasonable choice. Complex cases involving fertility preservation, pituitary masses, or Klinefelter syndrome warrant specialist referral.

Medi-Cal Covers Testosterone Cypionate with Prior Authorization

Medi-Cal, California's Medicaid program, lists testosterone cypionate on its formulary for the treatment of male hypogonadism, but coverage requires prior authorization (PA). The PA process confirms that the prescription meets clinical criteria.

The typical documentation package for Medi-Cal PA includes: (1) two morning total testosterone levels below 300 ng/dL drawn on separate days, (2) ICD-10 diagnosis code E29.1 (testicular hypofunction) or a related hypogonadism code, (3) documentation of symptoms such as fatigue, decreased libido, or loss of muscle mass, and (4) notation that reversible causes (opioid use, obesity, obstructive sleep apnea, hyperprolactinemia) have been evaluated. Approval decisions typically arrive within 24 to 72 hours for standard requests. Urgent requests can be processed in 24 hours.

For patients with commercial insurance through plans like Kaiser Permanente, Blue Shield of California, or Anthem Blue Cross, coverage varies by plan but most cover generic testosterone cypionate at a Tier 2 or Tier 3 copay. A 10 mL vial of 200 mg/mL testosterone cypionate (the most common concentration) costs roughly $30 to $90 at retail pharmacies without insurance, making it one of the least expensive injectable testosterone formulations available. GoodRx and similar discount platforms may reduce this further.

Dr. Shalender Bhasin, principal investigator of several landmark testosterone trials at Brigham and Women's Hospital, noted in the Endocrine Society guideline: "We recommend against testosterone therapy in men planning fertility in the near term" (Bhasin et al., 2018). This point matters for younger California patients seeking TRT: exogenous testosterone suppresses spermatogenesis, and providers should discuss fertility preservation before initiating treatment.

503A Compounding Pharmacies in California

California's Board of Pharmacy licenses 503A compounding pharmacies that may prepare patient-specific testosterone cypionate prescriptions. A 503A pharmacy compounds medications pursuant to an individual prescription, unlike 503B outsourcing facilities that produce larger batches without patient-specific prescriptions.

Compounded testosterone cypionate from a 503A pharmacy can offer advantages. Prescribers may specify custom concentrations (for example, 100 mg/mL instead of the standard 200 mg/mL) for patients needing smaller, more precise dose adjustments. Some compounding pharmacies also prepare testosterone cypionate in grape seed oil or sesame oil bases as alternatives for patients who react to the cottonseed oil used in many commercial products.

California 503A pharmacies may ship compounded testosterone cypionate to patients within the state. They cannot ship across state lines unless they register as a 503B outsourcing facility with the FDA. When choosing a compounded product, verify that the pharmacy holds an active California Board of Pharmacy license and follows USP 797 sterile compounding standards. The FDA's page on compounding provides additional guidance on what to look for.

Compounded testosterone cypionate typically costs $40 to $120 for a 10 mL vial depending on concentration and oil base. Pricing is competitive with commercial generics, though insurance plans may not cover compounded versions.

The Step-by-Step Process from Consultation to First Injection

Getting started is more straightforward than many patients expect. Here is the typical timeline.

Days 1 to 2: You schedule a telehealth or in-person consultation and complete a health questionnaire. The provider orders lab work. You visit a local Quest or Labcorp draw site for a fasting morning blood draw.

Days 3 to 7: Lab results return. If total testosterone is below 300 ng/dL, your provider reviews results and schedules a follow-up consultation (often the same day results post). A second confirmatory draw may be required if only one low reading exists.

Day 7 to 10: The provider writes the prescription. For telehealth platforms, the prescription is sent to a partner pharmacy or a 503A compounder. For in-person visits, you may take the prescription to any California pharmacy.

Days 10 to 14: You receive your testosterone cypionate, syringes, and alcohol swabs by mail or pick them up locally. Most platforms include injection training via video.

Some telehealth providers compress this timeline to under 7 days by using same-day lab partnerships and rapid PA processing. If you already have qualifying lab work from the past 6 months, the process may start even faster.

Dosing Protocols and Self-Injection Basics

The standard starting dose for testosterone cypionate ranges from 100 to 200 mg per week, administered as an intramuscular (IM) or subcutaneous (SubQ) injection. Many clinicians now prefer twice-weekly dosing (splitting the weekly dose into two smaller injections) to maintain more stable serum levels and reduce estradiol spikes.

A 2014 pharmacokinetic study found that subcutaneous testosterone cypionate injections produced bioequivalent serum testosterone levels compared with intramuscular injections, with lower peak-to-trough variability (Al-Futaisi et al., Transl Androl Urol, 2017). SubQ injections use a shorter needle (typically 25 to 27 gauge, 5/8 inch), cause less pain, and are easier for self-administration. The abdomen and thigh are the most common SubQ sites.

Follow-up labs are typically drawn 6 to 8 weeks after starting therapy, timed at the trough (the morning before your next injection). Target trough total testosterone is 400 to 700 ng/dL for most men, though the Endocrine Society guideline states the goal is the "mid-normal range" (Bhasin et al., 2018). Hematocrit, PSA, and estradiol are rechecked at 3 to 6 months, then annually.

Transferring an Existing Prescription to California

If you move to California with an active testosterone cypionate prescription from another state, the transfer process is straightforward but has a few requirements.

California pharmacies accept prescription transfers from out-of-state pharmacies for Schedule III controlled substances. Your new California pharmacy contacts your previous pharmacy to verify the prescription and remaining refills. You will need a California-licensed prescriber to write future prescriptions once your current refills expire, because an out-of-state provider cannot indefinitely prescribe to a California address.

Telehealth makes this transition simple. You can establish care with a California-licensed provider before your existing refills run out. Bring your most recent lab work and treatment records to avoid unnecessary repeat testing. Most providers accept labs performed within the past 6 months for continuity of care purposes.

The DEA requires that controlled substance prescriptions be written by a provider licensed in the state where the patient resides, though a brief overlap period for prescription transfers is permitted. Plan ahead: do not wait until your last vial is empty to find a California provider.

Monitoring and Long-Term Safety

Long-term TRT requires consistent monitoring. The TRAVERSE trial (N=5,246), published in 2023, provided the largest safety dataset for testosterone therapy to date. It found no significant increase in major adverse cardiovascular events (MACE) in men aged 45 to 80 with hypogonadism and preexisting or high risk for cardiovascular disease treated with transdermal testosterone versus placebo over a mean follow-up of 33 months (Lincoff et al., NEJM, 2023). This trial directly addressed the FDA's 2015 boxed warning requirement, and the FDA subsequently revised testosterone labeling in 2024.

Polycythemia remains the most common laboratory adverse effect. The TRAVERSE trial reported hematocrit exceeding 54% in 7.5% of testosterone-treated men versus 2.0% on placebo. Standard practice calls for dose reduction, therapeutic phlebotomy, or temporary discontinuation if hematocrit exceeds 54%.

Annual monitoring should include: total testosterone trough level, CBC with hematocrit, PSA (men over 40), lipid panel, and hepatic function. Bone density screening (DEXA scan) may be appropriate for men with osteoporosis risk factors, as testosterone therapy has been shown to increase lumbar spine bone mineral density by 7.7% over 12 months in the T-Trials bone substudy (Snyder et al., JAMA Intern Med, 2017).